Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06315023 · ClinicalTrials.gov registry record
The Percutaneous Transmural Arterial Bypass -1 Study (Post Approval Registry)
A clinical trial of Peripheral Arterial Disease and Symptomatic Femoropopliteal Lesions, sponsored by Endologix.
- Recruiting
- Registry status
- 450
- Enrollment target
- 10
- Study locations
NCT06315023 is a study of Peripheral Arterial Disease and Symptomatic Femoropopliteal Lesions that is actively recruiting participants, run by Endologix. The registered enrollment target is 450 participants, below the 4,201-participant average among 79 other Peripheral Arterial Disease trials with a reported enrollment target (89% lower). The trial reports 10 study locations across 9 states.
The verdict
NCT06315023, a study of Peripheral Arterial Disease and Symptomatic Femoropopliteal Lesions, is actively recruiting participants, sponsored by Endologix.
- RECRUITING
- Registry status
- 450 participants
- Enrollment target
- 10
- Study locations
Study Summary
The purpose of this post-market surveillance study will be to evaluate the real-world use of the DETOUR System in treated patients with symptomatic femoropopliteal lesions from 200 mm to 460 mm in length with chronic total occlusions (100 mm to 425 mm) or diffuse stenosis \> 70% who may be considered suboptimal candidates for surgical or alternative endovascular treatments.
Conditions Studied
Interventions
- DEVICE DETOUR System
Study Locations (10)
Pennsylvania
- University of Pennsylvania - West Chester
- Main Line Health - Wynnewood
California
- Salinas Valley Memorial Hospital - Salinas
Connecticut
- University of Connecticut - Storrs
District of Columbia
- Medstar Washington Hospital Center - Washington D.C.
Florida
- Delray Medical Center - Delray Beach
Massachusetts
- Beth Isreal Deaconess Medical Center - Boston
Missouri
- Saint Luke's Hospital of Kansas City - Kansas City
New York
- NYU Langone Medical Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 450 participants |
| Start Date | 2023-10-06 |
| Est. Completion | 2032-06-07 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06315023
The ClinicalTrials.gov registry entry for NCT06315023 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 450 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,201-participant average among 79 other Peripheral Arterial Disease trials with a reported enrollment target (89% lower). The listed sponsor is Endologix, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Peripheral Arterial Disease appearing as the primary indexed condition, and to 1 intervention - of which DETOUR System is the first listed.
NCT06315023 reports 10 study locations spanning 9 distinct geographic areas - top geographies include Pennsylvania, California, Connecticut.
Frequently Asked Questions
What is clinical trial NCT06315023 about?
NCT06315023 is a clinical study titled "The Percutaneous Transmural Arterial Bypass -1 Study (Post Approval Registry)". The purpose of this post-market surveillance study will be to evaluate the real-world use of the DETOUR System in treated patients with symptomatic femoropopliteal lesions from 200 mm to 460 mm in length with chronic total occlusions (100 mm to 425 mm) or diffuse stenosis \> 70% who may be considere...
What is the current status of trial NCT06315023?
This trial is currently recruiting. The enrollment target is 450 participants. The study started on 2023-10-06. Estimated completion is 2032-06-07.
What conditions does trial NCT06315023 study?
This clinical trial studies the following conditions: Peripheral Arterial Disease, Symptomatic Femoropopliteal Lesions.
What interventions are being tested in trial NCT06315023?
The interventions under investigation include: DETOUR System (DEVICE).
Who is sponsoring clinical trial NCT06315023?
This trial is sponsored by Endologix, which has 17 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06315023 being conducted?
This trial has 10 study locations across California, Connecticut, District of Columbia, Florida, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Peripheral Arterial Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
SELUTION4BTK Trial
RECRUITING · NA
-
MitoQ Treatment of Claudication: Myofiber and Micro-vessel Pathology
RECRUITING · NA
-
A Real-World Registry of Chronic Wounds and Ulcers
RECRUITING
-
Low Dose ColchicinE in pAtients With Peripheral Artery DiseasE to Address Residual Vascular Risk
RECRUITING · Phase 3
-
Ramipril Treatment of Claudication: Oxidative Damage and Muscle Fibrosis
RECRUITING · Phase 4
-
Ultrasound Perfusion Estimation for Assessment of Peripheral Arterial Disease
RECRUITING · NA
Explore more on PlainTrial
Peripheral Arterial Disease
All registered trials for this condition
Symptomatic Femoropopliteal Lesions
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.